EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Börje Ljungberg,Karim Bensalah,Steven E. Canfield,Saeed Dabestani,Fabian Hofmann,Milan Hora,Markus A. Kuczyk,Thomas B. Lam,Lorenzo Marconi,Axel S. Merseburger,Peter F.A. Mulders,Thomas Powles,Michael Staehler,Alessandro Volpe,Axel Bex +14 more
TLDR
The 2014 RCC guideline has been updated by a multidisciplinary panel using the highest methodological standards, and provides the best and most reliable contemporary evidence base for RCC management.About:
This article is published in European Urology.The article was published on 2010-09-01 and is currently open access. It has received 3100 citations till now. The article focuses on the topics: Guideline & Systematic review.read more
Citations
More filters
Journal ArticleDOI
Renal cell carcinoma.
James J. Hsieh,Mark P. Purdue,Sabina Signoretti,Charles Swanton,Laurence Albiges,Manuela Schmidinger,Daniel Y. Heng,James Larkin,Vincenzo Ficarra +8 more
TL;DR: An overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy are provided.
Journal ArticleDOI
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
Börje Ljungberg,Laurance Albiges,Yasmin Abu-Ghanem,Karim Bensalah,Saeed Dabestani,Sergio Fernández-Pello,Rachel H. Giles,Fabian Hofmann,Milan Hora,Markus A. Kuczyk,Teele Kuusk,Thomas B. Lam,Lorenzo Marconi,Axel S. Merseburger,Thomas Powles,Michael Staehler,Rana Tahbaz,Alessandro Volpe,Axel Bex +18 more
TL;DR: These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019 and are thoroughly evaluated to establish international standards for the care of kidney cancer patients.
Journal ArticleDOI
Integrated molecular analysis of clear-cell renal cell carcinoma.
Yusuke Sato,Tetsuichi Yoshizato,Yuichi Shiraishi,Shigekatsu Maekawa,Yusuke Okuno,Takumi Kamura,Teppei Shimamura,Aiko Sato-Otsubo,Genta Nagae,Hiromichi Suzuki,Yasunobu Nagata,Kenichi Yoshida,Ayana Kon,Yutaka Suzuki,Kenichi Chiba,Hiroko Tanaka,Atsushi Niida,Akihiro Fujimoto,Tatsuhiko Tsunoda,Teppei Morikawa,Daichi Maeda,Haruki Kume,Sumio Sugano,Masashi Fukayama,Hiroyuki Aburatani,Masashi Sanada,Masashi Sanada,Satoru Miyano,Yukio Homma,Seishi Ogawa,Seishi Ogawa +30 more
TL;DR: This integrated molecular analysis of clear-cell renal cell carcinoma unmasked new correlations between DNA methylation, gene mutation and/or gene expression and copy number profiles, enabling the stratification of clinical risks for patients with ccRCC.
Journal ArticleDOI
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri,Bernard Escudier,Thomas Powles,Nizar M. Tannir,Paul N. Mainwaring,Brian I. Rini,Hans J. Hammers,Frede Donskov,Bruce J. Roth,K. Peltola,Jae-Lyun Lee,Daniel Y.C. Heng,Manuela Schmidinger,Neeraj Agarwal,Cora N. Sternberg,David F. McDermott,Dana T. Aftab,Colin Hessel,Christian Scheffold,Gisela Schwab,Thomas E. Hutson,Sumanta K. Pal,Robert J. Motzer +22 more
TL;DR: The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment.
Journal ArticleDOI
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer,Thomas E. Hutson,Hilary Glen,M. Dror Michaelson,Ana M. Molina,Timothy Eisen,Jacek Jassem,Jakub Zolnierek,J. P. Maroto,Begoña Mellado,Bohuslav Melichar,Jiri Tomasek,Alton Kremer,Han-Joo Kim,Karen Wood,Corina E. Dutcus,James Larkin +16 more
TL;DR: Lenvatinib plus everolimus and len vatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
BookDOI
TNM classification of malignant tumours
TL;DR: Head and Neck Tumours.- Lip and Oral Cavity.- Pharynx.- Larynx.' Maxillary Sinus.- Salivary Glands.- Thyroid Gland.- Digestive System Tumour .
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Related Papers (5)
The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth
Alexander Kutikov,Robert G. Uzzo +1 more